Bavarian Nordic (OTCMKTS:BVNRY) Sees Significant Decline in Short Interest

Bavarian Nordic (OTCMKTS:BVNRY) saw a large decrease in short interest in June. As of June 15th, there was short interest totaling 2,985 shares, a decrease of 79.8% from the May 31st total of 14,745 shares. Based on an average daily trading volume, of 4,713 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.0% of the shares of the stock are sold short.

Bavarian Nordic Stock Performance

Shares of Bavarian Nordic stock opened at $9.05 on Monday. The firm’s 50-day simple moving average is $9.67 and its 200-day simple moving average is $9.89. Bavarian Nordic has a twelve month low of $8.67 and a twelve month high of $13.00. The firm has a market cap of $2.15 billion, a P/E ratio of 11.91 and a beta of 1.19.

Bavarian Nordic (OTCMKTS:BVNRY) last posted its earnings results on Wednesday, May 13th. The company reported $0.01 earnings per share for the quarter. Bavarian Nordic had a net margin of 19.74% and a return on equity of 9.32%. The business had revenue of $165.70 million for the quarter.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.